ZA200601030B - Quinazoline derivatives as inhibitors of VEGF receptor tyrosine kinases - Google Patents
Quinazoline derivatives as inhibitors of VEGF receptor tyrosine kinases Download PDFInfo
- Publication number
- ZA200601030B ZA200601030B ZA200601030A ZA200601030A ZA200601030B ZA 200601030 B ZA200601030 B ZA 200601030B ZA 200601030 A ZA200601030 A ZA 200601030A ZA 200601030 A ZA200601030 A ZA 200601030A ZA 200601030 B ZA200601030 B ZA 200601030B
- Authority
- ZA
- South Africa
- Prior art keywords
- salkyl
- salkanoyl
- alkyl
- aminoc
- heterocyclic group
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title description 6
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 title description 4
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
- 125000000623 heterocyclic group Chemical group 0.000 claims description 96
- 125000001424 substituent group Chemical group 0.000 claims description 92
- 125000000217 alkyl group Chemical group 0.000 claims description 84
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 46
- 229920006395 saturated elastomer Polymers 0.000 claims description 44
- 125000005842 heteroatom Chemical group 0.000 claims description 39
- -1 methylenedioxy Chemical group 0.000 claims description 38
- 229910052757 nitrogen Inorganic materials 0.000 claims description 38
- 150000001875 compounds Chemical class 0.000 claims description 37
- 125000001589 carboacyl group Chemical group 0.000 claims description 33
- 229910052739 hydrogen Inorganic materials 0.000 claims description 33
- 239000001257 hydrogen Substances 0.000 claims description 33
- 229910052717 sulfur Inorganic materials 0.000 claims description 33
- 229910052760 oxygen Inorganic materials 0.000 claims description 30
- 125000005843 halogen group Chemical group 0.000 claims description 25
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 25
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 20
- 150000002431 hydrogen Chemical class 0.000 claims description 20
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 20
- 125000004043 oxo group Chemical group O=* 0.000 claims description 19
- 125000004122 cyclic group Chemical group 0.000 claims description 14
- 125000003709 fluoroalkyl group Chemical group 0.000 claims description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 13
- 125000003545 alkoxy group Chemical group 0.000 claims description 12
- 150000003839 salts Chemical class 0.000 claims description 11
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 7
- 230000000694 effects Effects 0.000 claims description 7
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 6
- 125000001188 haloalkyl group Chemical group 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 230000008728 vascular permeability Effects 0.000 claims description 5
- 241001465754 Metazoa Species 0.000 claims description 4
- 125000003282 alkyl amino group Chemical group 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 230000008569 process Effects 0.000 claims description 4
- 230000001772 anti-angiogenic effect Effects 0.000 claims description 3
- 125000001246 bromo group Chemical group Br* 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 230000001603 reducing effect Effects 0.000 claims description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 12
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 8
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 claims 8
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims 7
- 239000000203 mixture Substances 0.000 claims 7
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 6
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 claims 5
- 238000006243 chemical reaction Methods 0.000 claims 4
- 239000000126 substance Substances 0.000 claims 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 3
- 125000004429 atom Chemical group 0.000 claims 3
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 2
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 2
- JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 claims 2
- IWASYXNYJUYQBV-UHFFFAOYSA-N 1-[4-[2-[4-(4-bromo-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxyethyl]piperidin-1-yl]-2-(dimethylamino)ethanone Chemical compound N1=CN=C2C=C(OCCC3CCN(CC3)C(=O)CN(C)C)C(OC)=CC2=C1NC1=CC=C(Br)C=C1F IWASYXNYJUYQBV-UHFFFAOYSA-N 0.000 claims 1
- VYRBUOLLDDZYRU-UHFFFAOYSA-N 1-[4-[2-[4-(4-chloro-2-fluoroanilino)-6-methoxyquinazolin-7-yl]oxyethyl]piperidin-1-yl]-2-(dimethylamino)ethanone Chemical compound N1=CN=C2C=C(OCCC3CCN(CC3)C(=O)CN(C)C)C(OC)=CC2=C1NC1=CC=C(Cl)C=C1F VYRBUOLLDDZYRU-UHFFFAOYSA-N 0.000 claims 1
- BWYJJZBRYSADRP-UHFFFAOYSA-N 2-methoxyquinazoline Chemical compound C1=CC=CC2=NC(OC)=NC=C21 BWYJJZBRYSADRP-UHFFFAOYSA-N 0.000 claims 1
- 241000896693 Disa Species 0.000 claims 1
- 241001481828 Glyptocephalus cynoglossus Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 238000010511 deprotection reaction Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000001153 fluoro group Chemical group F* 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 claims 1
- 125000006239 protecting group Chemical group 0.000 claims 1
- 102220300875 rs1554026816 Human genes 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
- 239000011575 calcium Substances 0.000 description 14
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 12
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 12
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 5
- 201000011510 cancer Diseases 0.000 description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 5
- 102400001368 Epidermal growth factor Human genes 0.000 description 4
- 101800003838 Epidermal growth factor Proteins 0.000 description 4
- 230000033115 angiogenesis Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 229940116977 epidermal growth factor Drugs 0.000 description 4
- 230000003389 potentiating effect Effects 0.000 description 4
- 230000002792 vascular Effects 0.000 description 4
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 3
- 101150021185 FGF gene Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000026731 phosphorylation Effects 0.000 description 3
- 238000006366 phosphorylation reaction Methods 0.000 description 3
- 150000003246 quinazolines Chemical class 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000037260 Atherosclerotic Plaque Diseases 0.000 description 2
- 208000007766 Kaposi sarcoma Diseases 0.000 description 2
- 208000034038 Pathologic Neovascularization Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 102000016548 Vascular Endothelial Growth Factor Receptor-1 Human genes 0.000 description 2
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 2
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- BSFODEXXVBBYOC-UHFFFAOYSA-N 8-[4-(dimethylamino)butan-2-ylamino]quinolin-6-ol Chemical group C1=CN=C2C(NC(CCN(C)C)C)=CC(O)=CC2=C1 BSFODEXXVBBYOC-UHFFFAOYSA-N 0.000 description 1
- 206010051113 Arterial restenosis Diseases 0.000 description 1
- 108090000461 Aurora Kinase A Proteins 0.000 description 1
- 102100032311 Aurora kinase A Human genes 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- 206010013908 Dysfunctional uterine bleeding Diseases 0.000 description 1
- 201000009273 Endometriosis Diseases 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010025282 Lymphoedema Diseases 0.000 description 1
- 206010027514 Metrorrhagia Diseases 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 101000852966 Rattus norvegicus Interleukin-1 receptor-like 1 Proteins 0.000 description 1
- 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 1
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000003185 calcium uptake Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 208000002502 lymphedema Diseases 0.000 description 1
- 208000002780 macular degeneration Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- AHLKSOXEVRYIRD-UHFFFAOYSA-N n-phenylquinazolin-2-amine Chemical class N=1C=C2C=CC=CC2=NC=1NC1=CC=CC=C1 AHLKSOXEVRYIRD-UHFFFAOYSA-N 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000003450 potassium channel blocker Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 230000009919 sequestration Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 230000006426 vascular sprouting Effects 0.000 description 1
- 230000004862 vasculogenesis Effects 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Manufacturing & Machinery (AREA)
- Ceramic Engineering (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Structural Engineering (AREA)
- Materials Engineering (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Reproductive Health (AREA)
- Ophthalmology & Optometry (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Transplantation (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0318423.1A GB0318423D0 (en) | 2003-08-06 | 2003-08-06 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200601030B true ZA200601030B (en) | 2007-05-30 |
Family
ID=27839733
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200601030A ZA200601030B (en) | 2003-08-06 | 2006-02-03 | Quinazoline derivatives as inhibitors of VEGF receptor tyrosine kinases |
Country Status (14)
Country | Link |
---|---|
US (1) | US20070027145A1 (es) |
EP (1) | EP1653965A1 (es) |
JP (1) | JP2007501212A (es) |
KR (1) | KR20060058781A (es) |
CN (1) | CN1863534A (es) |
AU (1) | AU2004262982A1 (es) |
BR (1) | BRPI0413280A (es) |
CA (1) | CA2534422A1 (es) |
GB (1) | GB0318423D0 (es) |
IL (1) | IL173483A0 (es) |
MX (1) | MXPA06001394A (es) |
NO (1) | NO20060641L (es) |
WO (1) | WO2005013998A1 (es) |
ZA (1) | ZA200601030B (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE549329T1 (de) * | 2002-02-01 | 2012-03-15 | Astrazeneca Ab | Chinazoline verbindungen |
GB0519879D0 (en) | 2005-09-30 | 2005-11-09 | Astrazeneca Ab | Chemical process |
US7829574B2 (en) | 2008-05-09 | 2010-11-09 | Hutchison Medipharma Enterprises Limited | Substituted quinazoline compounds and their use in treating angiogenesis-related diseases |
SG10201510586PA (en) | 2008-06-30 | 2016-01-28 | Mesoblast Inc | Treatment of Eye Diseases And Excessive Neovascularization Using A Combined Therapy |
JP2013514379A (ja) * | 2009-12-15 | 2013-04-25 | ニユーロツプ・インコーポレイテツド | 神経障害の治療のための化合物 |
AR092289A1 (es) * | 2011-11-14 | 2015-04-15 | Sunshine Lake Pharma Co Ltd | Derivados de aminoquinazolina y sus sales y metodos de uso |
CN105330653A (zh) | 2014-08-11 | 2016-02-17 | 石药集团中奇制药技术(石家庄)有限公司 | 喹唑啉衍生物 |
US9854482B2 (en) * | 2015-04-21 | 2017-12-26 | International Business Machines Corporation | Controlling a delivery of voice communications over a cellular data network or a wireless network based on user's profile |
CA3012718A1 (en) | 2016-02-08 | 2017-08-17 | Vitrisa Therapeutics, Inc. | Compositions with improved intravitreal half-life and uses thereof |
CN106565681B (zh) * | 2016-11-10 | 2019-07-09 | 中国医学科学院放射医学研究所 | 含硝基咪唑基团的苯胺喹唑啉类化合物及其制备方法和应用 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9624482D0 (en) * | 1995-12-18 | 1997-01-15 | Zeneca Phaema S A | Chemical compounds |
DK0880508T3 (da) * | 1996-02-13 | 2003-06-30 | Astrazeneca Ab | Quinazolinderivater som VEGF-inhibitorer |
ATE211134T1 (de) * | 1996-03-05 | 2002-01-15 | 4-anilinochinazolin derivate | |
GB9718972D0 (en) * | 1996-09-25 | 1997-11-12 | Zeneca Ltd | Chemical compounds |
EP1119567B1 (en) * | 1998-10-08 | 2005-05-04 | AstraZeneca AB | Quinazoline derivatives |
HU228964B1 (en) * | 1999-02-10 | 2013-07-29 | Astrazeneca Ab | Quinazoline derivatives as angiogenesis inhibitors, process for their preparation and medicaments containing them |
ES2265998T3 (es) * | 1999-11-05 | 2007-03-01 | Astrazeneca Ab | Derivados de quizazolina como inhibidores de vegf. |
WO2001077085A1 (en) * | 2000-04-07 | 2001-10-18 | Astrazeneca Ab | Quinazoline compounds |
-
2003
- 2003-08-06 GB GBGB0318423.1A patent/GB0318423D0/en not_active Ceased
-
2004
- 2004-08-05 MX MXPA06001394A patent/MXPA06001394A/es unknown
- 2004-08-05 EP EP04801817A patent/EP1653965A1/en not_active Withdrawn
- 2004-08-05 BR BRPI0413280-7A patent/BRPI0413280A/pt not_active IP Right Cessation
- 2004-08-05 KR KR1020067002552A patent/KR20060058781A/ko not_active Application Discontinuation
- 2004-08-05 WO PCT/GB2004/003393 patent/WO2005013998A1/en active Application Filing
- 2004-08-05 CN CNA2004800288013A patent/CN1863534A/zh active Pending
- 2004-08-05 AU AU2004262982A patent/AU2004262982A1/en not_active Abandoned
- 2004-08-05 JP JP2006522409A patent/JP2007501212A/ja not_active Withdrawn
- 2004-08-05 CA CA002534422A patent/CA2534422A1/en not_active Abandoned
- 2004-08-05 US US10/566,841 patent/US20070027145A1/en not_active Abandoned
-
2006
- 2006-01-31 IL IL173483A patent/IL173483A0/en unknown
- 2006-02-03 ZA ZA200601030A patent/ZA200601030B/en unknown
- 2006-02-09 NO NO20060641A patent/NO20060641L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU2004262982A1 (en) | 2005-02-17 |
KR20060058781A (ko) | 2006-05-30 |
CN1863534A (zh) | 2006-11-15 |
NO20060641L (no) | 2006-05-03 |
US20070027145A1 (en) | 2007-02-01 |
WO2005013998A1 (en) | 2005-02-17 |
BRPI0413280A (pt) | 2006-10-10 |
MXPA06001394A (es) | 2006-05-19 |
JP2007501212A (ja) | 2007-01-25 |
CA2534422A1 (en) | 2005-02-17 |
IL173483A0 (en) | 2006-06-11 |
GB0318423D0 (en) | 2003-09-10 |
EP1653965A1 (en) | 2006-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200601030B (en) | Quinazoline derivatives as inhibitors of VEGF receptor tyrosine kinases | |
ZA200405908B (en) | Quinazoline compounds | |
ZA200601025B (en) | Quinazoline derivatives as angiogenesis inhibitors | |
JP5563950B2 (ja) | 組合せ療法 | |
ZA200106340B (en) | Quinazoline derivatives as angiogenesis inhibitors. | |
NO324471B1 (no) | Kinazolinforbindelser samt anvendelse og fremgangsmate for fremstilling derav og farmasoytisk sammensetning | |
AU2003249000B2 (en) | Combination of ZD6474, an inhibitor of the vasuclar endothelial growth factor receptor, with radiotherapy in the treatment of cancer | |
RU2425043C2 (ru) | Малеатные соли производного хиназолина, полезные в качестве антиангиогенного агента | |
KR20100135754A (ko) | 병용 요법 238 | |
JP2008514577A (ja) | Zd6474及びイマチニブを含んでなる組合せ | |
MXPA06000114A (es) | Uso del derivado de quinazolina zd6474 combinado con compuestos de platino y, opcionalmente, con radiacion ionizante, en el tratamiento de enfermedades asociadas con la angiogenesis y/o la permeabilidad vascular incrementada. | |
ZA200300489B (en) | Indole, azaindole and indazole derivatives having VEGF inhibiting activities. | |
WO2008125820A1 (en) | Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii | |
KR20060009893A (ko) | Src 억제제와 조합된 항혈관형성제를 포함하는 치료제및 이것의 치료 용도 | |
CN101175734B (zh) | 一种作为抗肿瘤药物的喹唑啉衍生物及其制备方法 | |
ZA200506211B (en) | Combination therapy of ZD6474 with 5-FU or/and CT-11 | |
US20080182985A1 (en) | Tyrosine kinase inhibitors | |
ZA200207382B (en) | Quinazoline compounds. |